drugset / Trial / NCT00516438
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
Timeline
- Start
- 2007-07
- Primary completion
- 2009-03
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | — | Oral |
| Subject | Topotecan | Small molecule | — | Intravenous |